Drugs / JHL1101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03161457 | Feb 2017 → Apr 2019 | rheumatoid arthritis | JHL Biotech, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT03670901 | Nov 2018 → Mar 2019 | diffuse large B-cell lymphoma | JHL Biotech, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JHL1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03670901 ↗ |
| Route | Intravenous | “2 intravenous infusions of 1000 mg JHL1101” NCT03161457 ↗ |